National Liver Cancer Screening Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), and HCC etiology (viral vs. non-viral). Patients will be recruited from 15 sites (mix of tertiary care and large community health systems) over a 3-year period, and the primary endpoint of the phase IV trial, reduction in late-stage HCC, will be assessed after 5.5 years.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-85 lat z marskością wątroby dowolnego pochodzenia lub przewlekłym zapaleniem wątroby B
- •Kwalifikacja do przesiewowania raka wątroby według lekarza prowadzącego
- •Możliwość wyrażenia świadomej zgody
- •Spodziewana długość życia powyżej 6 miesięcy
✗ Disqualifies
- •Zaawansowana marskość wątroby (klasa C)
- •Historia raka wątroby lub raka przewodów żółciowych
- •Guz w wątrobie o rozmiarze 1 cm lub większy bez potwierdzenia jego łagodności
- •Podwyższony marczer AFP bez badań potwierdzających brak podejrzanych zmian
- •Inne nowotwory (poza rakiem skóry) w ciągu ostatnich 2 lat
- •Planowana diagnostyka przesiewowa metodą MRI lub CT
- •Historia przeszczepu narządu
- •Umieszczenie na liście oczekujących na przeszczep wątroby
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 85 Years
- Last updated (source)
- August 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (19)
University of Southern California
Los Angeles, United States
Stanford University
Redwood City, United States
Kaiser Permanente
Roseville, United States
University of California, San Francisco
San Francisco, United States
Northwestern University
Chicago, United States
Indiana University
Indianapolis, United States
Massachusetts General Hospital
Boston, United States
University of Michigan
Ann Arbor, United States
Henry Ford Health System
Detroit, United States
Hennepin Healthcare
Minneapolis, United States
University of Minnesota
Minneapolis, United States
The Feinstein Institutes, Northwell Health, Inc.
Manhasset, United States
University of North Carolina
Chapel Hill, United States
Case Western Reserve University
Cleveland, United States
The Cleveland Clinic
Cleveland, United States
University of Pennsylvania
Philadelphia, United States
UT Southwestern Medical Center and Parkland Hospital
Dallas, United States
Baylor College of Medicine
Houston, United States
Virginia Commonwealth University
Richmond, United States
Trial contact
Amit Singal, MD, MS
Lisa Quirk, MS, MPH
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/13/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.